Berkeley Lights, Inc. and Novo Nordisk today announced that Novo Nordisk has purchased the Beacon®Optofluidic platform to accelerate workflows in cell line development and to use the platform for future protein and antibody discovery.

“We are committed to raising the height of our innovation by adopting new technologies that make drug discovery and development more efficient. The implementation of the platform from Berkeley Lights is in line with our ambition to drive a faster and more efficient path towards clinical development of lead candidates by increased investment in automation and digital capabilities,” said Lars Fogh Iversen, senior vice president, Global Research Technologies, Novo Nordisk.The Beacon platform reduces the extensive resources typically required to generate a cell line for commercial production by allowing for parallel screening, maintenance and analysis of thousands of cells. With the platform’s fully integrated and programmable workflow, the time expenditure for screening thousands of cells can be consolidated from 12 weeks to five days. Automating this process and combining it with the variety of assays supported by the platform increases efficiencies, reduces overall costs, and provides rich analytical insights into clone characteristics that are not currently available with traditional techniques for cell line development.“Drug discovery and development requires continuous improvement and innovation progress to drive efficiency and outcomes. Berkeley Lights’ digital cell biology platform offers the diversity, applicability and agility to meet these demands,” said Andy Last, chief commercial officer at Berkeley Lights. “We are pleased to have Novo Nordisk join our growing list of top pharma companies adopting the Beacon platform to propel cell line development and ultimately, to bring critical therapeutics to patients sooner.”To learn more about application of the Beacon®platform, please click hereAbout Novo NordiskNovo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 79 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

About Berkeley LightsBerkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development, and delivery of cell-based products and therapies.

At the intersection of biology, technology and information, our platforms automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. The Beacon platform* is ideally suited for cell line development, antibody discovery (including direct B cell workflows), gene editing, and antibody engineering workflows. Each workflow provides a 100 fold increase in insights, 10 times faster, at a fraction of the cost.

* For Research Use Only. Not for use in diagnostic procedures.

Further informationBerkeley Lights:Sandra Finley+1 408 386 6864email Sandra FinleySource: https://www.berkeleylights.com/novo-nordisk-purchases-berkeley-lights-beacon-optofluidic-platform-for-cell-line-development-and-antibody-discovery/